Executive Summary Vertex Pharmaceuticals' agreement to acquire Crinetics Pharmaceuticals creates an important new endocrine growth platform. The transaction brings PALSONIFY, a recently launched oral treatment for acromegaly, and atumelnant, a once-daily oral ACTH receptor antagonist now in Phase 3 development for classic congenital adrenal hyperplasia (CAH). Vertex has described the combined Crinetics portfolio as a potential multibillion-dollar peak-sales opportunity. Atumelnant may become a clinically meaningful advance, but its commercial potential…
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
